Tort tax cited at up to $5,000 as Demotech urges loss-cost change

Image
Tort tax cited at up to $5,000 as Demotech urges loss-cost change

UNITED STATES -- November 19, 2026 -- The "tort tax," the cost of the legal system embedded in the premium every policyholder pays, might be as much as $5,000 per year, a panel told the National Association of Professional Insurance Agents (PIA) at its Annual Leadership Conference and Advocacy Day, held Sept. 13-16, 2026. In the next presentation, Demotech President Joseph L. Petrelli argued that the loss-cost formula insurers have used since the 1980s cannot isolate litigation cost, and that litigated claims will become more frequent.

Demotech sponsors LDI Annual Conference 2026 in New Orleans

Image
Demotech sponsors LDI Annual Conference 2026 in New Orleans

NEW ORLEANS -- November 19, 2026 -- Demotech was a Bridge Sponsor of the 2026 LDI Annual Conference, held on Aug. 19 and 20 at the Hilton Riverside in New Orleans. Louisiana Insurance Commissioner Tim Temple and his senior leadership team led the two-day conference.

The theme was "Navigating the New Horizon." Demotech says attendees included regulators, elected officials, legislators, industry leaders and subject matter experts. According to the company, they focused on practical solutions to stabilize insurance markets and strengthen the resilience of insured structures.

Demotech urges NAIC to split loss costs by claim outcome

Image
Demotech urges NAIC to split loss costs by claim outcome

NEW CASTLE -- November 19, 2026 -- Demotech, Inc. president and co-founder Joseph L. Petrelli told the NAIC Northeast Zone meeting in New Castle, New Hampshire, held Sept. 1-4, 2026, that insurance loss costs should be broken down by claim outcome. The current presentation of loss costs rests on claim frequency multiplied by claim severity alone. Petrelli wants regulators to also track claims closed without payment, closed with payment, and outstanding.

New Hampshire Insurance Commissioner DJ Bettencourt, vice chair of the Northeast Zone, invited Petrelli to speak.

MTMIC cites $45M dividends, No. 8 Michigan workers' comp rank

Image
MTMIC cites $45M dividends, No. 8 Michigan workers' comp rank

MICHIGAN -- November 19, 2026 -- Manufacturing Technology Mutual Insurance Company (MTMIC) says it has paid more than $45 million in policyholder dividends and ranks eighth among Michigan workers' compensation carriers by written premium. The insurer traces its origin to a self-insured fund started in 1976, 50 years ago.

MTMIC converted to a mutual insurer on Jan. 1, 2007. By our calculation, the fund therefore operated for 31 years (1976 to 2007), about 62% of the 50-year span. The mutual structure has existed for almost 20 years.

A state limit on membership classes pushed the fund to become a mutual in 2007

Michigan legislation passed in the 1960s let similar industries pool assets for workers' compensation under joint and several liability. The Detroit Tooling Association used it in 1976. Membership was limited to classifications considered part of the tool and die industry.

IAB Tech Lab defines six CTV ad formats outside the break

Image
IAB Tech Lab defines six CTV ad formats outside the break

GLOBAL -- November 19, 2026 -- The IAB Tech Lab CTV Ad Portfolio now defines six ad placements outside the commercial break, leaving the break as one of seven places an ad can run in a connected-TV session, according to InTheGame (ITG) CEO Aviram Sharon. By our calculation, six of the seven placement types, about 86%, sit outside the break. On most CTV services, Sharon says, the entire ad load still runs in a handful of two- to four-minute interruptions.

FreeWheel study ties viewer irritation to break placement, not to ads themselves

A 2024 FreeWheel study, reported by eMarketer, found that breaks placed at unnatural moments bothered 71% of viewers and cut brand recall by 14%. Programming with well-placed ads was rated as enjoyable as programming with none.

Publishers have had two levers so far: fewer breaks or shorter ones. Sharon says both buy viewer experience at the cost of revenue.

TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials

Image
TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported that TONMYA fibromyalgia treatment beat placebo on both the symptoms and function domains of the Fibromyalgia Impact Questionnaire-Revised (FIQR) at Week 14 in two Phase 3 trials. The result was significant at p≤0.001 in RESILIENT and nominally significant at p0.01 in RELIEF.

Tonix presented the analysis at the IASP 2026 World Congress on Pain in Bangkok, held October 26-30, 2026. That is about 11 months after the November 2025 commercial launch of the drug, which the FDA approved on August 15, 2025.

Tonix schedules two TNX-801 vaccine sessions at Amsterdam congress

Image
Tonix schedules two TNX-801 vaccine sessions at Amsterdam congress

BERKELEY HEIGHTS -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) scheduled two sessions on its TNX-801 horsepox-based vaccine platform at World Vaccine Congress Europe in Amsterdam on Oct. 19-21, 2026. The company still lists the program as pre-IND, with a Phase 1 study not expected before 2027.

Tonix announced the sessions on Oct. 15, 2026, four days before the congress opened. Three of the four named speakers are Tonix employees. The fourth comes from the Kenya Medical Research Institute (KEMRI).

Tonix adds 21 million Medicare lives for TONMYA in second payer deal

Image
Tonix adds 21 million Medicare lives for TONMYA in second payer deal

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced on September 22, 2026 a second managed Medicare agreement for its fibromyalgia drug TONMYA, adding about 21 million Medicare lives. Medicare coverage for TONMYA now totals 32 million lives, or 58% of about 55 million Medicare lives in the U.S.

The agreement took effect immediately. By our calculation, it nearly triples earlier Medicare coverage: 32 million minus 21 million leaves about 11 million lives before the deal, roughly 20% of the Medicare population, against 58% now.

Total payer coverage for TONMYA reaches 53% of U.S. lives

Tonix says commercial and government coverage now totals about 166 million lives, 53% of about 314 million U.S. lives. Medicare accounts for about 19% of that total (32 million of 166 million). By our calculation, about 148 million lives, or 47%, remain outside coverage.

Tonix names Thomas Englese its first chief commercial officer

Image
Tonix names Thomas Englese its first chief commercial officer

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) promoted Thomas Englese to chief commercial officer, effective immediately, in an announcement dated Sept. 8, 2026. CEO Seth Lederman calls it the company's first CCO appointment. Englese had held the title of executive vice president, commercial operations, since September 2024, which works out to two years.

Englese keeps three marketed products across two indications

He continues to direct sales, marketing, market access and commercial operations for three products. TONMYA (cyclobenzaprine HCl sublingual tablets) is for fibromyalgia in adults. Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) are both for acute migraine in adults.

The release describes no change in scope. What changes is the title: the commercial organization for all three products now sits under a named C-suite officer.

REalloys, JS Link sign non-binding LOI for U.S. rare earth magnets

Image
REalloys, JS Link sign non-binding LOI for U.S. rare earth magnets

EUCLID, Ohio -- November 19, 2026 -- REalloys Inc. (NASDAQ: ALOY) and South Korea's JS Link Inc. (KOSDAQ: 127120) announced a non-binding letter of intent on July 7, 2026 to evaluate a North American rare earth magnet manufacturing platform. The deal would add permanent magnet production, the fourth stage of the chain the parties describe (feedstock, separation, metallization, magnets), to REalloys' existing business.

The letter of intent commits neither party to a transaction

The document is a framework for due diligence and for negotiating potential definitive agreements. The parties say they will evaluate manufacturing, commercialization, strategic customer relationships and U.S. government-supported financing programs. They also plan to evaluate future public capital markets initiatives, including a publicly traded North American magnet platform. The release does not disclose a deal value, ownership split, magnet capacity or timetable.